대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Combined Use of Empagliflozin and Liraglutide Protect Against Tacrolimus-Induced Pancreatic and Kidney Injury Through Suppression of Oxidative Stress
저자	Do hyun Na
출판정보	2025; 2025(1):
키워드	Post-transplant DM, Tacrolimus, SGLT2i, GLP1-RA, nephrotoxicity
초록	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are newer antidiabetic drugs for the treatment of type II diabetes mellitus (DM). This study aimed to investigate the protective effect of the combined use of empagliflozin (EMPA)(SGLT2i) and liraglutide (LIRA)(GLP-1RA) on tacrolimus (TAC)-induced pancreatic and kidney injury. Sprague-Dawley rats were divided into six groups, each containing six rats, and treated with a low-salt diet and TAC (1.5 mg/kg/day, subcutaneously) for 4 weeks. In addition to TAC, EMPA (10 mg/kg/day, oral gavage), LIRA (0.2 mg/kg/day or 0.4 mg/kg/day subcutaneously q12hrs) and a combination of both were administered. The protective effects of EMPA and LIRA were evaluated by assessing HbA1c levels, creatinine clearance rate, and markers of oxidative stress and apoptosis. Histological changes in the kidneys and pancreas were observed. TAC treatment significantly impaired kidney and pancreatic function and histological findings while increasing oxidative stress and apoptosis. Monotherapy with EMPA or LIRA partially alleviated these effects; however, the combination of both drugs provided the most substantial protective effects. Notably, combination treatment reduced HbA1c levels, improved creatinine clearance, decreased tubulointerstitial fibrosis, and enhanced pancreatic beta-cell area. Furthermore, combination treatment more effectively decreased TAC-induced oxidative stress and apoptosis in both pancreatic and kidney tissues. Combined use of EMPA and LIRA may offer a potent therapeutic strategy for managing TAC-induced kidney and pancreatic damage.
원문(PDF)	PDF 원문보기

목록

위로가기